This protocol addresses patients with newly diagnosed multiple myeloma who are aged under 70 years, carry no significant comorbidities, and are medically fit for autologous stem cell transplantation (ASCT). This specific eligibility profile — younger age and absence of comorbidities — defines the treatment pathway described here.
Current evidence-based guidelines recommend quadruplet induction regimens as the preferred standard of care in this population, followed by stem cell collection and high-dose conditioning before autologous transplantation — the complete regimen selection, consolidation, and maintenance strategy are set out in the full protocol.